Related Experiment Video
Updated: May 30, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Assessment of oral antithrombotic therapy by platelet function testing
Udaya S Tantry1, Paul A Gurbel
1Sinai Center for Thrombosis Research, Siani Hospital, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA.
Nature Reviews. Cardiology
|July 20, 2011
Summary
Platelet function testing may help personalize dual or triple antithrombotic therapy for patients with coronary artery disease and atrial fibrillation. This approach aims to reduce bleeding risk while preventing ischemic events.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dual antiplatelet therapy (clopidogrel and aspirin) prevents ischemic events in coronary artery disease.
- Warfarin is standard for thromboembolism prevention in atrial fibrillation.
- Triple antithrombotic therapy (dual antiplatelet therapy plus warfarin) is used in patients with both conditions, but increases bleeding risk.
Purpose of the Study:
- To review data on platelet function testing's utility in assessing bleeding risk.
- To explore the role of platelet function testing in personalizing antithrombotic therapy.
- To reduce ischemic events and bleeding complications.
Main Methods:
- Review of available data on platelet function testing.
- Analysis of its relationship with bleeding risk in dual and triple therapy.
- Investigation of its potential in personalized treatment strategies.
Main Results:
- Limited data currently exist on platelet function testing and bleeding in dual/triple therapy.
- Platelet function testing is under investigation for guiding therapy in coronary stent patients.
- Personalized strategies may optimize clinical benefit and minimize bleeding.
Conclusions:
- Platelet function testing shows potential for guiding personalized antithrombotic therapy.
- Further research is needed to establish its role in reducing bleeding and ischemic events.
- Personalized approaches are crucial for managing complex cardiovascular conditions.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...